Boston, MA 05/30/2013 (wallstreetpr) – The share prices of Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) had surged by 14.06 percent to close at $69.28 per share for the end of last trading session. The shares of the pharmaceutical company had been trading in the range of $63.68 to $71.82 per share during the day before closing at $8.54 per share increase over the previous day’s closing price.
Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) is a bio pharmaceutical company involved in the development and commercialization of treatment therapies for lipid disorders. The company had recently developed its first product candidate which is used as an oral once a day treatment for patients with inherited lipid disorders. The first product candidate of Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) named lomitapide was developed for the treatment of homozygous familial hypercholesterolemia.
The drug for treatment of inherited lipid disorder developed by Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) was further given orphan drug designation by the Food and Drugs Administration of the United States in 2011.
The recent increase in share prices of the drug development company had resulted in Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) touching new levels of high prices in 52 weeks. The shares of the pharmaceutical company had thereby recorded new 52 week high price level at $71.82 per share at the close of last trading session while the 52 week low price level is at $12.86 per share. Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) presently holds 28.81 million shares outstanding in the market with an institutional ownership of 108 percent of its holdings.
